SCHEMBL24596359

SCHEMBL24596359

CC1(C)OB(c2ccc(C(F)(F)F)cc2N)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CFTR P13569 1/20 0.39
L3MBTL1 Q9Y468 4/20 0.38
LMNA P02545 2/20 0.38
RAB9A P51151 1/20 0.38
MAPT P10636 3/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
GFER P55789 1/20 0.36
KMT2A Q03164 1/20 0.36
LIPE Q05469 6/20 0.36
ATM Q13315 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
LPL P06858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30990845 0.90 ALDH1A1 (0.38) ALDH1A1KDM4EPKMHPGDHSD17B10
SCHEMBL44941 0.90 ALDH1A1 (0.38) ALDH1A1KDM4EPKMHPGDHSD17B10
SCHEMBL25797776 0.85 ALDH1A1 (0.44) ALDH1A1PKMHPGDHSD17B10RAB9A
SCHEMBL837370 0.83 LIPE (0.39) MAPTLIPELPLLIPG
SCHEMBL30847591 0.82 CES2 (0.39) LIPELPLLIPG
SCHEMBL29314788 0.82 CES2 (0.39) LIPELPLLIPG
SCHEMBL29909454 0.82 PDE2A (0.39) GAALIPELPLLIPG
SCHEMBL4108381 0.82 PDE2A (0.39) GAALIPELPLLIPG
SCHEMBL17450049 0.81 LIPE (0.34) LIPELPLLIPG
SCHEMBL837116 0.81 PDE2A (0.41) ALDH1A1MAPTLIPETSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655287-A2 INHIBITORS OF NLRP3 MWYNGIL THERAPEUTICS, INC. (US) 2025-12-03 EP disclosed
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2025-10-02 US disclosed
EP-4526293-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME Repare Therapeutics Inc. (CA) 2025-03-26 EP disclosed
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 US disclosed
WO-2024158941-A2 INHIBITORS OF NLRP3 MWYNGIL THERAPEUTICS, INC. (US) 2024-08-02 WO disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
WO-2023220831-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2023-11-23 WO disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-11-03 US disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
EP-3966196-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 ALDH1A1 1477/4885KDM4E 1036/4885PKM 4666/4885
US-20220347176-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS ERAP1, CHP1, QSOX1 ALDH1A1 1546/4885KDM4E 1040/4885PKM 4579/4885
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME CSNK1A1, CSNK1G1, CSNK2A1 ALDH1A1 4490/4885KDM4E 2698/4885PKM 932/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 ALDH1A1 1431/4885KDM4E 1035/4885PKM 4631/4885
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A ALDH1A1 1518/4885KDM4E 2337/4885PKM 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.